6:07 PM
 | 
Mar 11, 2009
 |  BC Extra  |  Top Story

Rituxan misses lupus nephritis endpoint

Genentech (NYSE:DNA) and Biogen Idec (NASDAQ:BIIB) said top-line data showed that Rituxan rituximab plus mycophenolate mofetil missed the primary endpoint of reducing disease activity at 52 weeks...

Read the full 129 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >